Dr. Grothey on the DESTINY-CRC01 Trial With Trastuzumab Deruxtecan in HER2+ CRC


In Partnership With:

Axel Grothey, MD, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer.

Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses the DESTINY-CRC01 trial in patients with HER2-positive colorectal cancer (CRC).

In the DESTINY-CRC01 trial, a population of patients with HER2-overexpressing CRC were treated with fam-trastuzumab deruxtecan-nxki (Enhertu), Grothey says. The antibody-drug conjugate (ADC) links the trastuzumab (Herceptin) HER2 antibody with a strong topoisomerase inhibitor as a payload that is then integrated into the cell. The linker between the antibody and topoisomerase cleaves, the cytotoxic agent is released, and the cell dies, resulting in a bystander effect on surrounding cells.

The ADC was examined in a later-line setting in patients who were previously treated with HER2-targeted agents. Regardless of whether patients had previously been pretreated with HER2-targeted agents, trastuzumab deruxtecan elicited significant responses within this patient population, some of which proved to be durable, Grothey concludes.

Related Videos
Patrick Boland, MD
David S. Hong, MD
David Sommerhalder, MD
Jeremy C. Jones, MD
Marwan G. Fakih, MD
Howard S. Hochster, MD
Daneng Li, MD
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on breast cancer